Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217080958> ?p ?o ?g. }
- W3217080958 endingPage "100857" @default.
- W3217080958 startingPage "100857" @default.
- W3217080958 abstract "PurposeWe sought to examine the prognostic value of fluorodeoxyglucose-positron emission tomography (PET) imaging during chemoradiation for unresectable non-small cell lung cancer for survival and hypothesized that tumor PET response is correlated with peripheral T-cell function.Methods and MaterialsForty-five patients with American Joint Committee on Cancer version 7 stage IIB-IIIB non-small cell lung cancer enrolled in a phase II trial and received platinum-doublet chemotherapy concurrent with 6 weeks of radiation (NCT02773238). Fluorodeoxyglucose-PET was performed before treatment start and after 24 Gy of radiation (week 3). PET response status was prospectively defined by multifactorial radiologic interpretation. PET responders received 60 Gy in 30 fractions, while nonresponders received concomitant boosts to 74 Gy in 30 fractions. Peripheral blood was drawn synchronously with PET imaging, from which germline DNA sequencing, T-cell receptor sequencing, and plasma cytokine analysis were performed.ResultsMedian follow-up was 18.8 months, 1-year overall survival (OS) 82%, 1-year progression-free survival 53%, and 1-year locoregional control 88%. Higher midtreatment PET total lesion glycolysis was detrimental to OS (1 year 87% vs 63%, P < .001), progression-free survival (1 year 60% vs 26%, P = .044), and locoregional control (1 year 94% vs 65%, P = .012), even after adjustment for clinical/treatment factors. Twenty-nine of 45 patients (64%) were classified as PET responders based on a priori definition. Higher tumor programmed death-ligand 1 expression was correlated with response on PET (P = .017). Higher T-cell receptor richness and clone distribution slope were associated with improved OS (P = .018-0.035); clone distribution slope was correlated with PET response (P = .031).ConclusionsMidchemoradiation PET imaging is prognostic for survival; PET response may be linked to tumor and peripheral T-cell biomarkers." @default.
- W3217080958 created "2021-12-06" @default.
- W3217080958 creator A5001784443 @default.
- W3217080958 creator A5014218728 @default.
- W3217080958 creator A5018476396 @default.
- W3217080958 creator A5023007142 @default.
- W3217080958 creator A5035062387 @default.
- W3217080958 creator A5035477951 @default.
- W3217080958 creator A5036480949 @default.
- W3217080958 creator A5036889393 @default.
- W3217080958 creator A5058265665 @default.
- W3217080958 creator A5062492688 @default.
- W3217080958 creator A5063427877 @default.
- W3217080958 creator A5067794684 @default.
- W3217080958 creator A5070493081 @default.
- W3217080958 creator A5073998569 @default.
- W3217080958 creator A5080374314 @default.
- W3217080958 creator A5090508593 @default.
- W3217080958 creator A5091168604 @default.
- W3217080958 date "2022-03-01" @default.
- W3217080958 modified "2023-10-18" @default.
- W3217080958 title "Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer" @default.
- W3217080958 cites W1488069418 @default.
- W3217080958 cites W1968899146 @default.
- W3217080958 cites W1984068275 @default.
- W3217080958 cites W1984284869 @default.
- W3217080958 cites W1999020268 @default.
- W3217080958 cites W2006772779 @default.
- W3217080958 cites W2012002553 @default.
- W3217080958 cites W2016692045 @default.
- W3217080958 cites W2055262996 @default.
- W3217080958 cites W2064641323 @default.
- W3217080958 cites W2066781454 @default.
- W3217080958 cites W2087189381 @default.
- W3217080958 cites W2110048017 @default.
- W3217080958 cites W2142624390 @default.
- W3217080958 cites W2142720921 @default.
- W3217080958 cites W2155263737 @default.
- W3217080958 cites W2160969096 @default.
- W3217080958 cites W2263280562 @default.
- W3217080958 cites W2282156262 @default.
- W3217080958 cites W2324181757 @default.
- W3217080958 cites W2395655065 @default.
- W3217080958 cites W2528306813 @default.
- W3217080958 cites W2554542172 @default.
- W3217080958 cites W2578888194 @default.
- W3217080958 cites W2604331415 @default.
- W3217080958 cites W2609649761 @default.
- W3217080958 cites W2621243763 @default.
- W3217080958 cites W2624608718 @default.
- W3217080958 cites W2747686285 @default.
- W3217080958 cites W2753065806 @default.
- W3217080958 cites W2804492207 @default.
- W3217080958 cites W2887382620 @default.
- W3217080958 cites W2888597303 @default.
- W3217080958 cites W2893824814 @default.
- W3217080958 cites W2897984913 @default.
- W3217080958 cites W2899389328 @default.
- W3217080958 cites W2923431558 @default.
- W3217080958 cites W2980537150 @default.
- W3217080958 cites W2985106162 @default.
- W3217080958 cites W3002420685 @default.
- W3217080958 cites W3010184812 @default.
- W3217080958 cites W3096305909 @default.
- W3217080958 cites W3119904172 @default.
- W3217080958 cites W3124783762 @default.
- W3217080958 cites W3126006083 @default.
- W3217080958 cites W3132585350 @default.
- W3217080958 cites W615537915 @default.
- W3217080958 doi "https://doi.org/10.1016/j.adro.2021.100857" @default.
- W3217080958 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35387421" @default.
- W3217080958 hasPublicationYear "2022" @default.
- W3217080958 type Work @default.
- W3217080958 sameAs 3217080958 @default.
- W3217080958 citedByCount "1" @default.
- W3217080958 crossrefType "journal-article" @default.
- W3217080958 hasAuthorship W3217080958A5001784443 @default.
- W3217080958 hasAuthorship W3217080958A5014218728 @default.
- W3217080958 hasAuthorship W3217080958A5018476396 @default.
- W3217080958 hasAuthorship W3217080958A5023007142 @default.
- W3217080958 hasAuthorship W3217080958A5035062387 @default.
- W3217080958 hasAuthorship W3217080958A5035477951 @default.
- W3217080958 hasAuthorship W3217080958A5036480949 @default.
- W3217080958 hasAuthorship W3217080958A5036889393 @default.
- W3217080958 hasAuthorship W3217080958A5058265665 @default.
- W3217080958 hasAuthorship W3217080958A5062492688 @default.
- W3217080958 hasAuthorship W3217080958A5063427877 @default.
- W3217080958 hasAuthorship W3217080958A5067794684 @default.
- W3217080958 hasAuthorship W3217080958A5070493081 @default.
- W3217080958 hasAuthorship W3217080958A5073998569 @default.
- W3217080958 hasAuthorship W3217080958A5080374314 @default.
- W3217080958 hasAuthorship W3217080958A5090508593 @default.
- W3217080958 hasAuthorship W3217080958A5091168604 @default.
- W3217080958 hasBestOaLocation W32170809583 @default.
- W3217080958 hasConcept C121608353 @default.
- W3217080958 hasConcept C126322002 @default.
- W3217080958 hasConcept C143998085 @default.
- W3217080958 hasConcept C199374082 @default.